OUTTHUNDER BETA

CHYM

Researched 2026-10-30 16:59 UTC

EntryPriceDayTotal
29.35
Oct 29 close 28.87
Now 12:59 ET 28.26
−2.1%−3.7%
34.5525.5016.4428.87Volume34.9MClose21-day50-day200-dayMay 1Aug 3Oct 29

CHYM assessment (latest close $28.87, 2026-10-29). Your entry is $29.35, so the position is about 1.6% underwater (about 0.4 ATR).

1. Trend The close is 0.8% (0.20 ATR) below the 21-day average of $29.09, which is rising (+1.1% over 3 sessions). It is 4.9% (1.34 ATR) below the 50-day average of $30.36, which is falling (−1.3% over 10 sessions). This is a pullback against the short average but a downtrend against the medium one. Six of the last 10 sessions closed lower, and the stock is 16.4% below its 52-week high of $34.55.

2. Bull case

  • Earnings growth: Consensus for the quarter ended September 2026 is EPS $0.09 (+160% y/y) on revenue of $705.18M (+29.7%), per a Zacks/Yahoo preview. Q2 revenue rose 27%, and MyPay transaction profit more than tripled to $73M on $4.5B of originations with a 0.9% loss rate. Consensus sits above the August 5 Q3 guidance of $680–690M, so it depends on a raise. A Zacks item (Oct 8) says guidance was raised to $705M, but I could not confirm that against a company source.
  • Stride Bank: The $590M cash acquisition would make Chime a bank owner rather than a partner-bank client. The Motley Fool (Sep 9) cites over $100M in net synergies. This reduces the partner-bank dependence it flags as a structural risk, but closing is expected in H1 2027, so it adds nothing to near-term results.
  • Estimate revisions: Deutsche Bank upgraded to Buy (Oct 8, target $35), lifting its FY27 adjusted EBITDA estimate by about $71M to $778M. That is a revision in the company's favour, though it was issued at a price near $28, so it is not a fresh endorsement at today's level.

3. Bear case

  • Trend: The stock is 1.34 ATR below a falling 50-day average, and six of the last ten sessions were down. Until it reclaims $30.36, the trend is not repaired.
  • Valuation: A 32.05x forward P/E (Zacks, Oct 28) prices in the Q3 delivery. I cannot test it against fundamentals because that data was unavailable.
  • Estimate pressure: The earnings ESP is negative: −5.10% in the Oct 29 preview, though an Oct 28 Zacks piece cites −1.20%. Either way, the estimate bar has moved against a clean beat.
  • Thesis question unresolved: The results do not show whether MyPay and interchange growth will hold against competitors or survive earned-wage-access regulation. Nothing quantifies regulatory impact for CHYM. The November 4 report is the first real test.

Market context is not a bear bullet. CHYM's 63-session correlation is only 0.31 with FINX, 0.25 with ARKF and 0.19 with SPY, so driver-based reasoning (the tech selloff) does not explain its moves well.

4. Reconciliation Bullish coverage (consensus "Moderate Buy," $36.38 target) sits against a falling price. I follow the price. The $36.38 consensus is dated Oct 22, when the stock was at $30.37, and the stock has since fallen about 1.5 ATR, so that target is stale. The Monness Neutral $31 target (Oct 26, set near $28.68) is the post-move view.

Excluded evidence: Evergreen's 86% stake cut and Penn Mutual's purchase are 13F holdings filings. The insider sales (Oct 13, 50,000

Technical analysis: computed from daily prices as of 2026-10-29. Not an input to the decision above: each is scored against SPY on its own.

  • MACD (12, 26, 9): BEARISH, below its signal line, crossed 2 sessions ago (2026-10-27). Line -0.09, signal -0.04, histogram -0.05 and widening.
  • Awesome Oscillator (5, 34): BEARISH, below zero, crossed 1 session ago (2026-10-28). -0.29 and falling.
  • Chaikin Money Flow (20): BULLISH, buying pressure: volume is backing the up days, crossed 7 sessions ago (2026-10-20). +0.11 and rising.

Dive deep

Market overview of 2026-10-30 16:47 UTC →